Nektar Therapeutics | Income Statement
Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
148,921.00
200,707.00
230,784.00
165,436.00
307,711.00
1,193
Cost of Goods Sold (COGS) incl. D&A
38,509.00
35,170.00
40,619.00
38,163.00
37,522.00
30
Gross Income
110,412.00
165,537.00
190,165.00
127,273.00
270,189.00
1,163
SG&A Expense
219,242.00
182,022.00
216,536.00
240,128.00
309,150.00
475
EBIT
108,830.00
16,485.00
-
112,855.00
38,961.00
688
Unusual Expense
11,300.00
-
14,079.00
-
20,681.00
-
Non Operating Income/Expense
392.00
814.00
1,680.00
2,387.00
4,520.00
38
Interest Expense
40,762.00
38,757.00
38,901.00
42,180.00
40,954.00
43
Pretax Income
159,768.00
54,428.00
80,671.00
152,648.00
96,076.00
683
Income Tax
2,245.00
512.00
506.00
876.00
616.00
1
Consolidated Net Income
162,013.00
53,916.00
81,177.00
153,524.00
96,692.00
681
Net Income
162,013.00
53,916.00
81,177.00
153,524.00
96,692.00
681
Net Income After Extraordinaries
162,013.00
53,916.00
81,177.00
153,524.00
96,692.00
681
Net Income Available to Common
162,013.00
53,916.00
81,177.00
153,524.00
96,692.00
681
EPS (Basic)
1.40
0.42
0.61
1.10
0.62
3.78
Basic Shares Outstanding
115,732.00
126,873.00
132,458.00
139,596.00
155,953.00
170
EPS (Diluted)
1.40
0.42
0.61
1.10
0.62
3.78
Diluted Shares Outstanding
115,732.00
126,873.00
132,458.00
139,596.00
155,953.00
180
EBITDA
94,555.00
3,558.00
13,516.00
97,504.00
24,220.00
697
Non-Operating Interest Income
732.00
-
-
-
-
-
About Nektar Therapeutics
View Profile
